These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10418530)

  • 1. An effective way to manage breakthrough pain.
    Scholz M
    RN; 1999 May; 62(5):102. PubMed ID: 10418530
    [No Abstract]   [Full Text] [Related]  

  • 2. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
    Mercadante S; Villari P; Ferrera P; Casuccio A; Mangione S; Intravaia G
    Br J Cancer; 2007 Jun; 96(12):1828-33. PubMed ID: 17519902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated strategies for the successful management of breakthrough cancer pain.
    Dickman A
    Curr Opin Support Palliat Care; 2011 Mar; 5(1):8-14. PubMed ID: 21325998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tramadol and strong opioid: synergistic or additive opioid effect?
    Di Lorenzo L
    Pain Pract; 2008; 8(3):214-5; author reply 215-6. PubMed ID: 18476900
    [No Abstract]   [Full Text] [Related]  

  • 5. Pain levels within 24 hours after UFE: a comparison of morphine and fentanyl patient-controlled analgesia.
    Kim HS; Czuczman GJ; Nicholson WK; Pham LD; Richman JM
    Cardiovasc Intervent Radiol; 2008; 31(6):1100-7. PubMed ID: 18797963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral transmucosal fentanyl: new preparation. For breakthrough cancer pain when morphine fails.
    Prescrire Int; 2002 Aug; 11(60):106-7. PubMed ID: 12199262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do patients prefer transdermal fentanyl or sustained-release oral morphine for treatment of chronic non-cancer pain?
    Heidemann AJ; Seaton TL
    J Fam Pract; 2001 Oct; 50(10):897. PubMed ID: 11674896
    [No Abstract]   [Full Text] [Related]  

  • 8. Fentanyl buccal tablet (Fentora) for breakthrough pain.
    Med Lett Drugs Ther; 2007 Sep; 49(1270):78-9. PubMed ID: 17878889
    [No Abstract]   [Full Text] [Related]  

  • 9. Methadone: an effective alternative to morphine for pain relief in cancer patients.
    Shelton BW; Deynes-Romero J; Tofani-Montalvo M; Ramírez-Rivera J; Jaumne-Anselmi F
    Bol Asoc Med P R; 2008; 100(3):7-10. PubMed ID: 19227708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 3 analgesic regimens on the perception of pain after removal of femoral artery sheaths.
    Fulton TR; Peet GI; McGrath MA; Hilton JD; Smith RE; Sigurdsson AF; Forrest QG
    Am J Crit Care; 2000 Mar; 9(2):125-9. PubMed ID: 10705425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioids for management of breakthrough pain in cancer patients.
    Potter MB
    Am Fam Physician; 2006 Dec; 74(11):1855-7. PubMed ID: 17168339
    [No Abstract]   [Full Text] [Related]  

  • 12. Transdermal fentanyl: new preparation. An alternative to morphine.
    Prescrire Int; 1998 Oct; 7(37):137-40. PubMed ID: 10915416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy switching in patients receiving long-acting opioids.
    Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
    Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
    Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
    J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of pain-related behavior, bone destruction and effectiveness of fentanyl, sufentanil, and morphine in a murine model of cancer pain.
    El Mouedden M; Meert TF
    Pharmacol Biochem Behav; 2005 Sep; 82(1):109-19. PubMed ID: 16125759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of angina pectoris pain: morphine or thalamonal?].
    Hoke RS
    Dtsch Med Wochenschr; 2001 Oct; 126(43):1221-2. PubMed ID: 11677650
    [No Abstract]   [Full Text] [Related]  

  • 18. Continuous intrathecal morphine infusion in patients with vertebral fractures due to osteoporosis.
    Shaladi A; Saltari MR; Piva B; Crestani F; Tartari S; Pinato P; Micheletto G; Dall'Ara R
    Clin J Pain; 2007; 23(6):511-7. PubMed ID: 17575491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxycodone-induced analgesic effects in a bone cancer pain model in mice.
    Kato A; Minami K; Ito H; Tomii T; Matsumoto M; Orita S; Kihara T; Narita M; Suzuki T
    Oncology; 2008; 74 Suppl 1():55-60. PubMed ID: 18758199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R; Likar R; Nautrup BP
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.